US stock · Healthcare sector · Biotechnology
Company Logo

Apellis Pharmaceuticals, Inc.

APLSNASDAQ

58.32

USD
-2.77
(-4.53%)
Market Closed
-9.74P/E
-12Forward P/E
-0.49P/E to S&P500
6.407BMarket CAP
- -Div Yield

Apellis Pharmaceuticals, Inc.

NASDAQ:APLS

RECENT
PRICE

58.32

P/E
RATIO

-9.74

(PEG:- -)

P/E RATIO
RELATIVE
TO S&P

-0.49

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.51 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 09/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

- -

- -

- -

- -

- -

- -

- -

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

(0.22)

(0.19)

- -

- -

(0.60)

(0.55)

- -

- -

(2.57)

(1.04)

- -

- -

(1.51)

(1.44)

- -

- -

(3.68)

(3.36)

- -

- -

(2.34)

(2.41)

- -

- -

(4.90)

(3.42)

- -

3.33

(4.59)

(2.21)

- -

0.89

(9.93)

(7.51)

- -

1.05

(7.02)

(6.66)

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

0.25

0.00

0.73

- -

1.93

- -

1.32

- -

10.74

- -

2.96

0.03

0.55

0.07

2.72

0.01

2.64

0.01

2.55

CAPEX per share

Book Value per share

- -

- -

- -

- -

- -

- -

- -

18

18

18

18

14

54

62

75

75

92

Comm.Shares outs.(m)

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

(4.4)

(0.2)

- -

(8.3)

(0.3)

- -

(4.6)

(0.2)

- -

(7.5)

(0.2)

- -

(5.0)

(0.2)

- -

(9.7)

(0.5)

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (30/6/22 | Q2)

Total liabilities
$668 m.

Total assets
$1,002 m.

Long-term debt
$189 m.

Cash and equiv.
$604 m.

Goodwill - -

Retained earnings $(1,952) m.

Common stock 98 m. shares

Market Capitalisation
$6,407 m. (as of 25/9/22)

- -

- -

- -

- -

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

251

(85.3)%

67

(805.7)%

97

(1,055.4)%

Revenue (m)

Operating margin

- -

- -

- -

- -

0

(4)

0

(11)

- -

(47)

- -

(27)

0

(51)

- -

(128)

0

(305)

1

(345)

1

(746)

1

(638)

Depreciation (m)

Net profit (m)

- -

- -

- -

- -

- -

(Infinity)%

3.9%

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

- -

(Infinity)%

(0.5)%

(137.6)%

(0.0)%

(1,121.3)%

(0.4)%

(1,407.1)%

Income tax rate

Net profit margin

- -

- -

- -

- -

- -

- -

5

- -

5

13

- -

13

35

- -

35

24

- -

24

175

26

149

185

25

161

307

143

34

789

359

205

692

206

199

833

189

334

Working capital (m)

Long-term debt (m)

Equity (m)

- -

- -

- -

- -

- -

- -

(89.1)%

(77.5)%

(87.6)%

(82.0)%

(78.9)%

(81.6)%

18.3%

16.8%

(133.0)%

(114.7)%

(99.4)%

(114.0)%

(28.9)%

(27.9)%

(34.2)%

(67.1)%

(61.5)%

(79.2)%

(89.0)%

(74.0)%

(890.2)%

(37.8)%

(32.6)%

(168.6)%

(97.8)%

(83.1)%

(375.7)%

(70.4)%

(61.3)%

(190.9)%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

352

566

640

Receivables

- -

- -

10

Inventory

- -

- -

16

Other

21

40

97

Current assets

373

917

824

Acc. Payable

8

8

17

Debt due

3

4

4

Other

55

116

111

Current liab.

66

128

132

- -

- -

- -

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

Apellis Pharmaceuticals, Inc. (US) started trading on November 4, 2017 (cik: 0001492422), operates in the Healthcare sector (Biotechnology industry), has 476 full-time employees, and is led by DR. Cedric Francois. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

- -

- -

Cash flow

115.47%

- -

Earnings

104.64%

- -

Dividends

- -

- -

Book value

106.02%

- -

Insider trading

Type

Shares

Date

Machiels Alec

Exempt

1,250

09/15/22

Machiels Alec

Sale

1,250

09/15/22

Machiels Alec

Exempt

1,250

09/15/22

Deschatelets Pascal

Exempt

18,500

09/08/22

Deschatelets Pascal

Sale

12,000

09/08/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

- -

- -

1

250

251

2021

- -

1

6

60

67

2022

14

16

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

(2.25)

(1.58)

(1.81)

1.04

-4.59

2021

(2.44)

(2.92)

(2.60)

(1.97)

-9.93

2022

(1.42)

(1.59)

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -